Literature DB >> 1483045

Epidemiology of neuromuscular disorders in the under-20 population in Bologna Province, Italy.

L Merlini1, S B Stagni, E Marri, C Granata.   

Abstract

A retrospective epidemiological survey of the principal neuromuscular disorders was undertaken in the population under the age of 20 yr in Bologna city and province. The incidence of Duchenne muscular dystrophy (DMD) proved to be 25.8 x 10(-5), that is, comparable with the outcome of neonatal screening studies. The incidence of spinal muscular atrophy (SMA) was very high (11.2 x 10(-5), probably the result of our greater awareness and recognition of this disorder. The prevalence of neuromuscular disorders in the 0-19 yr population is 1.5 times that in the general population; that of DMD is 28 x 10(-5) vs 6.3 x 10(-5) and that of the SMA 6.5 x 10(-5) vs 1.2 x 10(-5). Our results indicate that neuromuscular disorders, particularly DMD and SMA I and II, have a much higher prevalence in the first two decades of life than is generally thought. Awareness of the higher prevalence of neuromuscular disorders among the under-20s is essential to the adequate planning of medical services.

Entities:  

Mesh:

Year:  1992        PMID: 1483045     DOI: 10.1016/0960-8966(92)90006-r

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  13 in total

1.  Prevalence of Duchenne and Becker muscular dystrophies in the United States.

Authors:  Paul A Romitti; Yong Zhu; Soman Puzhankara; Katherine A James; Sarah K Nabukera; Gideon K D Zamba; Emma Ciafaloni; Christopher Cunniff; Charlotte M Druschel; Katherine D Mathews; Dennis J Matthews; F John Meaney; Jennifer G Andrews; Kristin M Caspers Conway; Deborah J Fox; Natalie Street; Melissa M Adams; Julie Bolen
Journal:  Pediatrics       Date:  2015-02-16       Impact factor: 7.124

2.  Therapeutic developments in spinal muscular atrophy.

Authors:  Douglas M Sproule; Petra Kaufmann
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

3.  Natural history of denervation in SMA: relation to age, SMN2 copy number, and function.

Authors:  Kathryn J Swoboda; Thomas W Prior; Charles B Scott; Teresa P McNaught; Mark C Wride; Sandra P Reyna; Mark B Bromberg
Journal:  Ann Neurol       Date:  2005-05       Impact factor: 10.422

4.  Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year.

Authors:  Petra Kaufmann; Michael P McDermott; Basil T Darras; Richard Finkel; Peter Kang; Maryam Oskoui; Andrei Constantinescu; Douglas Michael Sproule; A Reghan Foley; Michele Yang; Rabi Tawil; Wendy Chung; Bill Martens; Jacqueline Montes; Jessica O'Hagen; Sally Dunaway; Jean M Flickinger; Janet Quigley; Susan Riley; Allan M Glanzman; Maryjane Benton; Patricia A Ryan; Carrie Irvine; Christine L Annis; Hailly Butler; Jayson Caracciolo; Megan Montgomery; Jonathan Marra; Benjamin Koo; Darryl C De Vivo
Journal:  Arch Neurol       Date:  2011-02-14

5.  SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Thomas O Crawford; Louise R Simard; Sandra P Reyna; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan L Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; John T Kissel
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

6.  Vitamin D intake is inadequate in spinal muscular atrophy type I cohort: correlations with bone health.

Authors:  Jennifer Aton; Rebecca Hurst Davis; Kristine C Jordan; Charles B Scott; Kathryn J Swoboda
Journal:  J Child Neurol       Date:  2013-01-17       Impact factor: 1.987

7.  Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures.

Authors:  Alberto Lerario; Serena Bonfiglio; MariaPia Sormani; Andrea Tettamanti; Sarah Marktel; Sara Napolitano; Stefano Previtali; Marina Scarlato; MariaGrazia Natali-Sora; Eugenio Mercuri; Nereo Bresolin; Tiziana Mongini; Giancarlo Comi; Roberto Gatti; Fabio Ciceri; Giulio Cossu; Yvan Torrente
Journal:  BMC Neurol       Date:  2012-09-13       Impact factor: 2.474

8.  SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy.

Authors:  John T Kissel; Charles B Scott; Sandra P Reyna; Thomas O Crawford; Louise R Simard; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; Kathryn J Swoboda
Journal:  PLoS One       Date:  2011-07-06       Impact factor: 3.240

9.  Duchenne and Becker Muscular Dystrophies' Prevalence in MD STARnet Surveillance Sites: An Examination of Racial and Ethnic Differences.

Authors:  Yanan Zhang; Joshua R Mann; Katherine A James; Suzanne McDermott; Kristin M Conway; Pangaja Paramsothy; Tiffany Smith; Bo Cai
Journal:  Neuroepidemiology       Date:  2021-01-21       Impact factor: 3.282

10.  Phase II open label study of valproic acid in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; Charles B Scott; Sandra P Reyna; Thomas W Prior; Bernard LaSalle; Susan L Sorenson; Janine Wood; Gyula Acsadi; Thomas O Crawford; John T Kissel; Kristin J Krosschell; Guy D'Anjou; Mark B Bromberg; Mary K Schroth; Gary M Chan; Bakri Elsheikh; Louise R Simard
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.